Drug Target Review – Issue #3 2015

In Issue #3 2015 of Drug Target Review:

• FOREWORD
  When 0.77% is greater than 1%: salutatory lessons from the Court of Appeal
  Jacob Gifford Head, Thomas More Chambers
• DRUG DEVELOPMENT
  Immunogenicity: anticipating and avoiding issues for biopharmaceutical development
  Paul Chamberlain, NDA Advisory Board
• MICROFLUIDICS
  Microfluidic technology: the next-generation drug discovery tool
  Kimberly Plevniak and Mei He, Kansas State University
• IN-DEPTH FOCUS: PROTEOMICS
  With articles from David J. Britton and Pedro R. Cutillas, Barts Cancer Institute, and Manfred Raida, National University of Singapore
• ION CHANNELS
  Small molecules versus biologics: the quest for the ideal Nav1.7 inhibitor
  Marzia Martina and Martin N. Perkins, National Research Council of Canada
• GPCR
  Exploiting functional selectivity of GPCRs in drug development
  Niklas Larsson and Torben Østerlund, AstraZeneca
• IN-DEPTH FOCUS: IMAGING
  Featuring articles from Dimitri Scholz and Jeremy C. Simpson, University College Dublin, University of Glasgow’s Rudi Marquez, plus Zuzana Flachbartova, University of Veterinary Medicine and Pharmacy. Q&A interview with Molecular Devices
• FLOW CYTOMETRY
  Flow cytometry: not just a box in a lab
  Rachael Walker, Babraham Institute
• ENZYMES
  Ubiquitin-specific proteases as druggable targets
  Mindy I. Davis and Anton Simeonov, National Institutes of Health